Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.
Semenistaya. Ekaterina E; Zvereva. Irina I; Thomas. Andreas A; Thevis. Mario M; Krotov. Grigory G; Rodchenkov. Grigory G
Key Findings
- After nasal GHRP‑2, the parent peptide disappears, but its free‑acid metabolite and a short fragment remain detectable in urine for up to 47 hours.
- GHRP‑1 metabolites are found up to 27 h, while GHRP‑6 is mostly unchanged and detectable for about 23 h, with its metabolites only for ~12 h.
- Hexarelin and Ipamorelin are heavily metabolized, with multiple fragments persisting even after the parent compound is gone.
- A validated ultra‑pressure liquid chromatography‑tandem mass spectrometry method can reliably detect both parent peptides and their key metabolites.
Practical Outcomes
- For biohackers, the main takeaway is that a single nasal dose of GHRP‑2 can be traced in urine for roughly two days, mainly via its metabolites. This means timing your dosing cycles around any planned drug testing is crucial. Knowing which metabolites linger helps you understand how the body clears these peptides and may guide you in choosing administration routes or dosing intervals to minimize detection risk.
Summary
The study looked at how long different growth‑hormone‑releasing peptides (GHRPs) and their breakdown products show up in urine after a single nasal dose. It found that the original peptide often disappears quickly, but smaller fragments (metabolites) can stick around for 1‑2 days, depending on the specific peptide. This matters for anyone using these compounds because it tells you how long they can be detected in a drug test and gives clues about how the body processes them.
Abstract
Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. Samples were collected for 2 days after administration, processed by solid-phase extraction on weak cation exchange cartridges and analyzed by means of nano-liquid chromatography - high resolution mass spectrometry. Six metabolites of GHRP-1 were identified. GHRP-1 in the parent form was not detected. GHRP-1 (2-4) free acid was detected in urine up to 27 h. GHRP-2, GHRP-2 free acid and GHRP-2 (1-3) free acid were detected in urine up to 47 h after administration. GHRP-6 was mostly excreted unchanged and detected in urine 23 h after administration, its metabolites were detectable for 12 h only. Hexarelin and Ipamorelin metabolized intensively and were excreted as a set of parent compounds with metabolites. Hexarelin (1-3) free acid and Ipamorelin (1-4) free acid were detected in urine samples after complete withdrawal of parent substances. GHRPs and their most prominent metabolites were included into routine ultra-pressure liquid chromatography-tandem mass spectrometry procedure. The method was fully validated, calibration curves of targeted analytes were obtained and excretion curves of GHRPs and their metabolites were plotted. Our results confirm that the detection window after GHRPs administration depends on individual metabolism, drug preparation form and the way of administration.
Study Information
pubmed
2015
2015-04-13T00:00:00.000Z
10.1002/dta.1787
39
14